Invo Fertility, Inc. (IVF) Stock Price & Analysis

Invo Fertility, Inc. (IVF) rose 6.87% to USD 1.4 as of June 10, 2026 at 02:21 UTC, according to Nexqual real-time market data.

IVF last closed at USD 1.31; the session ranged USD 1.29–1.41 on volume of 118,852 shares. Market capitalization is $2.50M, with a 52-week range of USD 1.27–183.6 (NCM). Source: Nexqual, June 10, 2026 at 02:21 UTC.

Key Statistics (as of June 10, 2026 at 02:21 UTC)

Technical Analysis (IVF)

Nexqual's technical model rates IVF "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:21 UTC.

Analyst Ratings (IVF)

Wall Street analysts rate IVF "None" based on 1 analysts, with a mean price target of USD 20 (range USD 20–20), per Nexqual as of June 10, 2026 at 02:21 UTC.

Earnings (IVF)

Source: Nexqual, June 10, 2026 at 02:21 UTC.

Financials & Fundamentals (IVF)

Source: Nexqual, June 10, 2026 at 02:21 UTC.

Financial Health Score (IVF)

Nexqual rates Invo Fertility, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:21 UTC.

Ownership (IVF)

Source: Nexqual, June 10, 2026 at 02:21 UTC.

Leadership (IVF)

Invo Fertility, Inc. is led by Steven M. Shum (age 54), CEO & Director, per Nexqual as of June 10, 2026 at 02:21 UTC.

Major Backers & Investors (IVF)

Notable institutional backers of Invo Fertility, Inc. include Mariner, LLC, Armistice Capital, LLC, Fidelity, according to Nexqual as of June 10, 2026 at 02:21 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 02:21 UTC.

From Invo Fertility, Inc.'s Latest SEC 10-K Filing (filed 2026-06-02)

Key Strengths & Strategy (as disclosed to the SEC)

• These include laws that prohibit the following:     These laws are subject to extensive and increasing enforcement by numerous federal, state, and local government agencies including the Office of Inspector General, the Department of Justice, the Centers for Medicare & Medicaid Services, and various state authorities.
• The SEC allows us to disclose important information by referring to it in that manner.
• Primarily, our INVO Centers seek to employ local, reputable physicians with strong ties to the OBGYN community.   INVOcell Device   Historically, our approach to marketing INVOcell was focused on identifying partners within targeted geographic regions that we believe could best support our efforts to expand access to advanced fertility treatment using the INVOcell and IVC procedure for the large number of underserved infertile people around the world.

Partnerships

• The total purchase price was approximately $760,000, consisting of $360,000 in cash, of which $210,000 was paid at closing, and $400,000 in Series D Preferred Stock.   As part of the acquisition structure, we acquired the clinic's non-medical business assets through Wood Violet, while the clinic's medical assets were acquired by Fertility, P.A., which entered into a long-term Management Services Agreement with Wood Violet.
• On the same date, we entered into an inducement letter agreement with FNL (the "AIR Exercise and Reload Agreement"), pursuant to which FNL exercised its Additional Investment Right to acquire 1,800 shares of Series C-2 Preferred with an aggregate stated value of $1,800,000 in exchange for $1,800,000 of principal, plus accrued and unpaid interest, under the Amended and Restated Debenture.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:21 UTC. This page is informational and not investment advice.